Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. GNTLF.PINK

Genetic Technologies Limited (GNTLF PINK) stock market data APIs

$0.07 0(0%) as of July 25, 2024
Price chart is built with Anychart

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Genetic Technologies Limited Financial Data Overview

0.07
0.07
-
0.07
0.07
0.0007-6.34
7 968 K
96 573 K
10 243 K
-0.0002
0.508
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GNTLF',
Type: 'Common Stock',
Name: 'Genetic Technologies Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000MKLK39',
ISIN: NULL,
CUSIP: NULL,
CIK: '1166272',
EmployerIdNumber: NULL,
FiscalYearEnd: 'June',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
HomeCategory: NULL,
IsDelisted: false,
}

Genetic Technologies Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 10 243 K
  • EBITDA -9 857 421
  • Earnings Per Share 0
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Genetic Technologies Limited Earnings via APIs

  • Latest Release 2021-06-30
  • EPS/Forecast 0

Get Genetic Technologies Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Genetic Technologies Limited latest news via APIs

US Patent Office Grants Patent for COVID-19 Risk Test

Genetic Technologies Ltd MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based te...
  • CENTERS FOR DISEASE CONTROL AND PREVENTION
  • COMPANY
  • DISEASE SEVERITY
  • FORWARD-LOOKING STATEMENTS
  • GENETIC TECHNOLOGIES
  • GENETIC TECHNOLOGIES LIMITED
  • GTG
  • RISK TEST
  • SEVERE DISEASE
  • THE COMPANY

GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and Australia

Genetic Technologies Ltd MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based te...
  • ACCREDITATION
  • ASSESSMENT TEST
  • AUSTRALIA
  • BREAST CANCER
  • COLORECTAL
  • COMPANY
  • CORONARY ARTERY DISEASE
  • GENETIC TECHNOLOGIES LIMITED
  • GTG
  • MELBOURNE
  • MULTI-TEST
  • NATA
  • OVARIAN CANCERS
  • RISK ASSESSMENT
  • THE COMPANY
Do you have any questions?
support@eodhistoricaldata.com